PROCOLLAGEN TYPE-III AMINOTERMINAL PEPTIDE IN SERUM IN IDIOPATHIC MYELOFIBROSIS AND ALLIED CONDITIONS - RELATION TO DISEASE-ACTIVITY AND EFFECT OF CHEMOTHERAPY

被引:41
作者
HASSELBALCH, H
JUNKER, P
HORSLEVPETERSEN, K
LISSE, I
BENTSEN, KD
机构
[1] HVIDOVRE UNIV HOSP, DEPT RHEUMATOL, COPENHAGEN, DENMARK
[2] HVIDOVRE UNIV HOSP, DEPT PATHOL, COPENHAGEN, DENMARK
[3] GENTOFTE HOSP, DEPT HAEMATOL C, COPENHAGEN, DENMARK
[4] SVENDBORG HOSP, DEPT MED, COPENHAGEN, DENMARK
[5] GENTOFTE HOSP, DEPT MED, COPENHAGEN, DENMARK
关键词
disease activity; myelofibrosis; procollagen III peptide;
D O I
10.1002/ajh.2830330105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The serum concentration of the aminoterminal propeptide of type III procollagen (PIIINP) was measured serially in patients with idiopathic myelofibrosis and other myeloproliferative syndromes. Two different assays were applied, the RIA‐gnost assay (Hoechst, Frankfurt, FRG) and a new equilibrium RIA for the N‐terminal propeptide of human type III procollagen (Farmos Diagnostica, Oulu, Finland). A positive correlation was found between the results obtained by the two RIA's (rho = 0.90. P < 0.001). The highest propeptide levels were recorded in patients with idiopathic myelofibrosis, particularly in those with active disease. Elevated serum PIIINP levels decreased during treatment with various cytotoxic drugs, including intensive chemotherapy. By contrast, serum PIIINP was unchanged or increased in patients undergoing interferon alpha‐2b therapy. Gel filtration of sera on Sephacryl S‐300 column (Pharmacia, Sweden) showed that smaller PIIINP related peptides dominated in healthy subjects and in osteomyelosclerosis with stable disease. Conversely, the relative proportion of intact propeptide increased in accelerating disease stages and acute myelofibrosis. In conclusion, the present study implicates serum PIIINP as a useful indicator of disease activity in idiopathic myelofibrosis. The propeptide also appears to be a sensitive sero‐marker of chemotherapy effect on fibrogenesis related to clonal myeloproliferation. Finally, the propeptide is suggested as an early predictor of relapse during cytotoxic therapy. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:18 / 26
页数:9
相关论文
共 17 条
  • [1] ARRAGO JP, 1984, PRESSE MED, V13, P2429
  • [2] ARRAGO JP, 1986, SCAND J HAEMATOL, V36, P288
  • [3] IS THE AMINOTERMINAL PROPEPTIDE OF TYPE-III PROCOLLAGEN DEGRADED IN THE LIVER - A STUDY OF TYPE-III PROCOLLAGEN PEPTIDE IN SERUM DURING LIVER-TRANSPLANTATION IN PIGS
    BENTSEN, KD
    BOESBY, S
    KIRKEGAARD, P
    HANSEN, CP
    JENSEN, SL
    HORSLEVPETERSEN, K
    LORENZEN, I
    [J]. JOURNAL OF HEPATOLOGY, 1988, 6 (02) : 144 - 150
  • [4] BERLIN NI, 1975, SEMIN HEMATOL, V12, P339
  • [5] GALTON DAG, 1982, BLOOD ITS DISORDERS, P877
  • [6] HASSELBALCH H, 1985, SCAND J HAEMATOL, V35, P550
  • [7] SERUM MARKERS FOR TYPE-IV COLLAGEN AND TYPE-III PROCOLLAGEN IN THE MYELOFIBROSIS-OSTEOMYELOSCLEROSIS SYNDROME AND OTHER CHRONIC MYELOPROLIFERATIVE DISORDERS
    HASSELBALCH, H
    JUNKER, P
    LISSE, I
    BENTSEN, KD
    RISTELI, L
    RISTELI, J
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1986, 23 (02) : 101 - 111
  • [8] INCREASED SERUM PROCOLLAGEN-III AMINOTERMINAL PEPTIDE IN MYELOFIBROSIS
    HOCHWEISS, S
    FRUCHTMAN, S
    HAHN, EG
    GILBERT, H
    DONOVAN, PB
    JOHNSON, J
    GOLDBERG, JD
    BERK, PD
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1983, 15 (04) : 343 - 351
  • [9] LASZLO J, 1975, SEMIN HEMATOL, V12, P409
  • [10] LEWIS SM, 1963, BRIT MED J, P472